Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee

A phase I dose-escalation trial

Yves Marie Pers, Lars Rackwitz, Rosanna Ferreira, Oliver Pullig, Christophe Delfour, Frank Barry, Luc Sensebe, Louis Casteilla, Sandrine Fleury, Philippe Bourin, Danièle Noël, François Canovas, Catherine Cyteval, Gina Lisignoli, Joachim Schrauth, Daniel Haddad, Sophie Domergue, Ulrich Noeth, Christian Jorgensen

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Osteoarthritis (OA) is the most wide spread musculoskeletal disorder in adults. It leads to cartilage damage associated with subchondral bone changes and synovial inflammation, causing pain and disability. The present study aimed at evaluating the safety of a dose-escalation protocol of intra-articular injected adipose-derived stromal cells (ASCs) in patients with knee OA, as well as clinical efficacy as secondary endpoint. A bicentric, uncontrolled, open phase I clinical trial was conducted in France and Germany with regulatory agency approval for ASC expansion procedure in both countries. From April 2012 to December 2013, 18 consecutive patients with symptomatic and severe knee OA were treated with a single intra-articular injection of autologous ASCs. The study design consisted of three consecutive cohorts (six patients each) with dose escalation: low dose (2 × 106 cells), medium dose (10 × 106), and high dose (50 × 106). The primary outcome parameter was safety evaluated by recording adverse events throughout the trial, and secondary parameters were pain and function subscales of the Western Ontario and McMaster Universities Arthritis Index. After 6 months of follow-up, the procedure was found to be safe, and no serious adverse events were reported. Four patients experienced transient knee joint pain and swelling after local injection. Interestingly, patients treated with low-dose ASCs experienced significant improvements in pain levels and function compared with baseline. Our data suggest that the intraarticular injection of ASCs is a safe therapeutic alternative to treat severe knee OA patients. A placebo-controlled double-blind phase IIb study is being initiated to assess clinical and structural efficacy.

Original languageEnglish
Pages (from-to)847-856
Number of pages10
JournalStem cells translational medicine
Volume5
Issue number7
DOIs
Publication statusPublished - 2016

Fingerprint

Knee Osteoarthritis
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Stromal Cells
Intra-Articular Injections
Pain
Safety
Clinical Trials, Phase I
Arthralgia
Ontario
Knee Joint
Osteoarthritis
France
Arthritis
Cartilage
Germany
Joints
Placebos
Inflammation
Bone and Bones

Keywords

  • Adipose mesenchymal stromal cells
  • Intra-articular injection
  • Osteoarthritis
  • Phase I clinical trial
  • Regenerative medicine
  • Therapeutic potential

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee : A phase I dose-escalation trial. / Pers, Yves Marie; Rackwitz, Lars; Ferreira, Rosanna; Pullig, Oliver; Delfour, Christophe; Barry, Frank; Sensebe, Luc; Casteilla, Louis; Fleury, Sandrine; Bourin, Philippe; Noël, Danièle; Canovas, François; Cyteval, Catherine; Lisignoli, Gina; Schrauth, Joachim; Haddad, Daniel; Domergue, Sophie; Noeth, Ulrich; Jorgensen, Christian.

In: Stem cells translational medicine, Vol. 5, No. 7, 2016, p. 847-856.

Research output: Contribution to journalArticle

Pers, YM, Rackwitz, L, Ferreira, R, Pullig, O, Delfour, C, Barry, F, Sensebe, L, Casteilla, L, Fleury, S, Bourin, P, Noël, D, Canovas, F, Cyteval, C, Lisignoli, G, Schrauth, J, Haddad, D, Domergue, S, Noeth, U & Jorgensen, C 2016, 'Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: A phase I dose-escalation trial', Stem cells translational medicine, vol. 5, no. 7, pp. 847-856. https://doi.org/10.5966/sctm.2015-0245
Pers, Yves Marie ; Rackwitz, Lars ; Ferreira, Rosanna ; Pullig, Oliver ; Delfour, Christophe ; Barry, Frank ; Sensebe, Luc ; Casteilla, Louis ; Fleury, Sandrine ; Bourin, Philippe ; Noël, Danièle ; Canovas, François ; Cyteval, Catherine ; Lisignoli, Gina ; Schrauth, Joachim ; Haddad, Daniel ; Domergue, Sophie ; Noeth, Ulrich ; Jorgensen, Christian. / Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee : A phase I dose-escalation trial. In: Stem cells translational medicine. 2016 ; Vol. 5, No. 7. pp. 847-856.
@article{bdbc8d8651684afda7b274aa56bc0d34,
title = "Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: A phase I dose-escalation trial",
abstract = "Osteoarthritis (OA) is the most wide spread musculoskeletal disorder in adults. It leads to cartilage damage associated with subchondral bone changes and synovial inflammation, causing pain and disability. The present study aimed at evaluating the safety of a dose-escalation protocol of intra-articular injected adipose-derived stromal cells (ASCs) in patients with knee OA, as well as clinical efficacy as secondary endpoint. A bicentric, uncontrolled, open phase I clinical trial was conducted in France and Germany with regulatory agency approval for ASC expansion procedure in both countries. From April 2012 to December 2013, 18 consecutive patients with symptomatic and severe knee OA were treated with a single intra-articular injection of autologous ASCs. The study design consisted of three consecutive cohorts (six patients each) with dose escalation: low dose (2 × 106 cells), medium dose (10 × 106), and high dose (50 × 106). The primary outcome parameter was safety evaluated by recording adverse events throughout the trial, and secondary parameters were pain and function subscales of the Western Ontario and McMaster Universities Arthritis Index. After 6 months of follow-up, the procedure was found to be safe, and no serious adverse events were reported. Four patients experienced transient knee joint pain and swelling after local injection. Interestingly, patients treated with low-dose ASCs experienced significant improvements in pain levels and function compared with baseline. Our data suggest that the intraarticular injection of ASCs is a safe therapeutic alternative to treat severe knee OA patients. A placebo-controlled double-blind phase IIb study is being initiated to assess clinical and structural efficacy.",
keywords = "Adipose mesenchymal stromal cells, Intra-articular injection, Osteoarthritis, Phase I clinical trial, Regenerative medicine, Therapeutic potential",
author = "Pers, {Yves Marie} and Lars Rackwitz and Rosanna Ferreira and Oliver Pullig and Christophe Delfour and Frank Barry and Luc Sensebe and Louis Casteilla and Sandrine Fleury and Philippe Bourin and Dani{\`e}le No{\"e}l and Fran{\cc}ois Canovas and Catherine Cyteval and Gina Lisignoli and Joachim Schrauth and Daniel Haddad and Sophie Domergue and Ulrich Noeth and Christian Jorgensen",
year = "2016",
doi = "10.5966/sctm.2015-0245",
language = "English",
volume = "5",
pages = "847--856",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee

T2 - A phase I dose-escalation trial

AU - Pers, Yves Marie

AU - Rackwitz, Lars

AU - Ferreira, Rosanna

AU - Pullig, Oliver

AU - Delfour, Christophe

AU - Barry, Frank

AU - Sensebe, Luc

AU - Casteilla, Louis

AU - Fleury, Sandrine

AU - Bourin, Philippe

AU - Noël, Danièle

AU - Canovas, François

AU - Cyteval, Catherine

AU - Lisignoli, Gina

AU - Schrauth, Joachim

AU - Haddad, Daniel

AU - Domergue, Sophie

AU - Noeth, Ulrich

AU - Jorgensen, Christian

PY - 2016

Y1 - 2016

N2 - Osteoarthritis (OA) is the most wide spread musculoskeletal disorder in adults. It leads to cartilage damage associated with subchondral bone changes and synovial inflammation, causing pain and disability. The present study aimed at evaluating the safety of a dose-escalation protocol of intra-articular injected adipose-derived stromal cells (ASCs) in patients with knee OA, as well as clinical efficacy as secondary endpoint. A bicentric, uncontrolled, open phase I clinical trial was conducted in France and Germany with regulatory agency approval for ASC expansion procedure in both countries. From April 2012 to December 2013, 18 consecutive patients with symptomatic and severe knee OA were treated with a single intra-articular injection of autologous ASCs. The study design consisted of three consecutive cohorts (six patients each) with dose escalation: low dose (2 × 106 cells), medium dose (10 × 106), and high dose (50 × 106). The primary outcome parameter was safety evaluated by recording adverse events throughout the trial, and secondary parameters were pain and function subscales of the Western Ontario and McMaster Universities Arthritis Index. After 6 months of follow-up, the procedure was found to be safe, and no serious adverse events were reported. Four patients experienced transient knee joint pain and swelling after local injection. Interestingly, patients treated with low-dose ASCs experienced significant improvements in pain levels and function compared with baseline. Our data suggest that the intraarticular injection of ASCs is a safe therapeutic alternative to treat severe knee OA patients. A placebo-controlled double-blind phase IIb study is being initiated to assess clinical and structural efficacy.

AB - Osteoarthritis (OA) is the most wide spread musculoskeletal disorder in adults. It leads to cartilage damage associated with subchondral bone changes and synovial inflammation, causing pain and disability. The present study aimed at evaluating the safety of a dose-escalation protocol of intra-articular injected adipose-derived stromal cells (ASCs) in patients with knee OA, as well as clinical efficacy as secondary endpoint. A bicentric, uncontrolled, open phase I clinical trial was conducted in France and Germany with regulatory agency approval for ASC expansion procedure in both countries. From April 2012 to December 2013, 18 consecutive patients with symptomatic and severe knee OA were treated with a single intra-articular injection of autologous ASCs. The study design consisted of three consecutive cohorts (six patients each) with dose escalation: low dose (2 × 106 cells), medium dose (10 × 106), and high dose (50 × 106). The primary outcome parameter was safety evaluated by recording adverse events throughout the trial, and secondary parameters were pain and function subscales of the Western Ontario and McMaster Universities Arthritis Index. After 6 months of follow-up, the procedure was found to be safe, and no serious adverse events were reported. Four patients experienced transient knee joint pain and swelling after local injection. Interestingly, patients treated with low-dose ASCs experienced significant improvements in pain levels and function compared with baseline. Our data suggest that the intraarticular injection of ASCs is a safe therapeutic alternative to treat severe knee OA patients. A placebo-controlled double-blind phase IIb study is being initiated to assess clinical and structural efficacy.

KW - Adipose mesenchymal stromal cells

KW - Intra-articular injection

KW - Osteoarthritis

KW - Phase I clinical trial

KW - Regenerative medicine

KW - Therapeutic potential

UR - http://www.scopus.com/inward/record.url?scp=84976351906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976351906&partnerID=8YFLogxK

U2 - 10.5966/sctm.2015-0245

DO - 10.5966/sctm.2015-0245

M3 - Article

VL - 5

SP - 847

EP - 856

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 7

ER -